Perspective Therapeutics, Inc. Logo

Perspective Therapeutics, Inc.

Developing targeted alpha radiotherapies using lead-212 to image and treat solid tumors.

CATX | US

Overview

Corporate Details

ISIN(s):
US46489V1044 (+1 more)
LEI:
Country:
United States of America
Address:
2401 ELLIOTT AVENUE, 98121 SEATTLE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Perspective Therapeutics, Inc. is a clinical-stage radiopharmaceutical company pioneering advanced treatments for cancer. The company specializes in developing image-guided, targeted alpha-particle therapies (TATs). Its proprietary technology platform uses a revolutionary lead-212 (Pb-212) based approach, conjugating radioisotopes to high-affinity targeting peptides. This theranostic method allows physicians to first image tumors to confirm targets and then deliver potent, short-range alpha radiation directly to cancer cells, aiming to maximize efficacy while minimizing damage to surrounding healthy tissue. The company's clinical pipeline is focused on oncology, with programs targeting melanoma, neuroendocrine tumors, and other solid tumors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Perspective Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Perspective Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Perspective Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Jyong Biotech Ltd. Logo
Develops plant-derived drugs for urinary system diseases, with a lead candidate in Phase III trials.
United States of America MENS
Kadimastem Ltd. Logo
Develops off-the-shelf stem cell therapies for diabetes & neurodegenerative diseases.
Israel KDST
kainos loboratories,inc Logo
Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.
Japan 4556
Kairos Pharma, LTD. Logo
Develops novel oncology therapies to reverse drug resistance and immune suppression.
United States of America KAPA
KAKEN PHARMACEUTIAL CO., LTD. Logo
R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.
Japan 4521
KALA BIO, Inc. Logo
Developing stem cell-based biologics for rare and serious eye diseases.
United States of America KALA
Kalaris Therapeutics, Inc. Logo
Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.
United States of America KLRS
KalVista Pharmaceuticals, Inc. Logo
Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).
United States of America KALV
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel KMDA
KAMADA LTD Logo
Develops specialty plasma-derived therapeutics for rare and serious diseases.
United States of America KMDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.